Investments and Fair Value Measurements - Ampreloxetine Funding (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
|---|---|---|---|
Mar. 31, 2025 |
Dec. 31, 2024 |
Jul. 31, 2022 |
|
| Development and Collaboration Agreement | |||
| Future royalty payment contingency | $ 30,977 | $ 30,334 | |
| Ampreloxetine Royalty Rights | |||
| Development and Collaboration Agreement | |||
| Milestone payments | $ 15,000 | ||
| Future royalty payment contingency | $ 30,977 | $ 30,334 | 25,000 |
| Percent of effective interest rate | 8.30% | ||
| Ampreloxetine Funding | |||
| Development and Collaboration Agreement | |||
| Consideration Receivable at closing | $ 25,000 |